Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide
    Metabolic & Weight LossPhase 3

    Cagrilintide Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about Cagrilintide dosing: protocols, safety, and where to buy.

    Frequency

    Once weekly

    Half-Life

    ~159 hours (approximately 7 days)

    Dosage Calculator

    Calculate exact dosing for Cagrilintide.

    Dosing Protocols

    Beginner

    Context: CagriSema is not yet FDA-approved (as of April 2026 — Phase 3 REDEFINE program complete, approval expected 2025-2026). This beginner protocol assumes either clinical trial enrollment, off-label compounded cagrilintide + semaglutide use, or early commercial availability.

    Preparation Phase (Weeks -2 to 0):

    • Confirm BMI ≥27 (with comorbidities) or ≥30 for obesity indication
    • Baseline labs: HbA1c, lipid panel, liver enzymes, TSH, testosterone (men), basic metabolic panel
    • Body composition baseline: DEXA scan (preferred) or impedance analysis
    • Medical history review: pancreatitis history, thyroid disease (MTC/MEN2 contraindicated), family history of thyroid cancer
    • Mental health screening: eating disorder history, depression
    • Weight history documentation
    • Discuss realistic expectations (20-22% weight loss at 68 weeks is the high end)

    Beginner Protocol (Weeks 1-16):

    CagriSema Initiation:

    • Week 1-4: Semaglutide 0.25 mg SC weekly + Cagrilintide 0.3 mg SC weekly
    • Week 5-8: Semaglutide 0.5 mg SC weekly + Cagrilintide 0.6 mg SC weekly
    • Week 9-12: Semaglutide 1.0 mg SC weekly + Cagrilintide 1.2 mg SC weekly
    • Week 13-16: Semaglutide 1.7 mg SC weekly + Cagrilintide 2.4 mg SC weekly
    • Week 17+: Semaglutide 2.4 mg + Cagrilintide 2.4 mg (full dose)

    Injection Timing:

    • Same day each week (typically Sunday or Monday)
    • Two separate injections (semaglutide and cagrilintide) — cannot be pre-mixed in same syringe
    • Can be same injection site area or different
    • Rotate sites to prevent irritation

    Administration:

    • Subcutaneous injection
    • Abdomen, thigh, or upper arm
    • 29-31G insulin syringes (5/16" or 1/2")
    • Clean site, inject slowly, brief pressure after
    • Dispose needle in sharps container

    Dietary Guidance:

    • Eat smaller portions — appetite will be significantly reduced
    • Prioritize protein: 1.6-2.0 g/kg ideal body weight to preserve lean mass
    • Adequate hydration: 2-3 L water daily
    • Moderate carbohydrate intake
    • Avoid late-night eating (gastric emptying already slowed)
    • Multivitamin supplementation

    Exercise Guidance:

    • Resistance training 2-3x weekly: preserve lean muscle mass during rapid weight loss
    • Compound movements: squats, deadlifts, presses, pulls
    • Progressive overload approach
    • Adequate recovery (weight loss is a stressor)
    • Cardiovascular: 150 min/week moderate OR 75 min/week vigorous

    Weeks 1-4 Expectations:

    • Initial GI side effects likely: nausea, appetite suppression, early satiety
    • Weight loss: typically 2-4% of body weight
    • Fatigue, especially with rapid weight loss
    • Mild dehydration risk

    Weeks 5-12 Expectations:

    • GI tolerance improves
    • Weight loss continues: typically 4-8% by week 12
    • Energy typically normalizes
    • Ongoing titration requires patience

    Week 16 Decision Points:

    • If full dose tolerated and weight loss on track: continue to intermediate protocol
    • If ongoing GI symptoms limiting dose: maintain current dose longer before escalating
    • If plateau: reassess calorie intake, exercise, adherence
    • If intolerable side effects: reduce dose or switch therapy

    Monitoring:

    • Weekly: body weight, blood pressure, subjective symptoms
    • Month 1: clinical check-in, adjust titration as needed
    • Month 3: comprehensive labs + body composition
    • Month 6: comprehensive labs + body composition + DEXA

    Red Flags Requiring Medical Attention:

    • Severe persistent nausea/vomiting with dehydration
    • Severe abdominal pain (pancreatitis concern)
    • Symptoms suggestive of gallbladder disease
    • Severe fatigue beyond expected
    • Mood changes or depression
    • Any signs of hypoglycemia (especially if diabetic)
    • Neck mass or thyroid-related symptoms

    What Beginner Protocol Does NOT Cover:

    • Maintenance dosing after initial 6-12 month weight loss phase
    • Management of weight regain after discontinuation
    • Pediatric use
    • Pregnancy (contraindicated)
    • Complex diabetic management (requires endocrinology co-management)
    Standard

    For users who have completed 16+ weeks of titration successfully and want to optimize long-term weight loss maintenance.

    Intermediate Protocol (Months 4-12):

    Full Maintenance Dose:

    • Semaglutide 2.4 mg SC weekly
    • Cagrilintide 2.4 mg SC weekly
    • Consistent weekly schedule
    • Most weight loss occurs in this phase

    Optimization Strategies:

    Protein Optimization:

    • 1.6-2.0 g/kg ideal body weight daily
    • Distribute across 3-4 meals (20-40 g per meal)
    • Leucine-rich sources preferred (dairy, meat, whey)
    • Consider whey protein supplementation if intake falls short

    Resistance Training Progression:

    • Progressive overload essential
    • 3-4 sessions weekly during stable dosing phase
    • Compound movements prioritized
    • Track strength metrics (not just weight)
    • Consider personal trainer or structured program

    Cardiovascular Exercise:

    • 150 minutes moderate-intensity OR 75 minutes vigorous weekly
    • HIIT 1-2x weekly for metabolic benefits
    • Walking for active recovery
    • Avoid overtraining (rest is part of program)

    Nutritional Quality:

    • Whole food emphasis
    • Adequate fiber (25-35 g daily)
    • Fatty fish 2x weekly for omega-3
    • Abundant vegetables for micronutrients
    • Limit ultra-processed foods

    Sleep Optimization:

    • 7-9 hours nightly
    • Consistent sleep/wake schedule
    • Appropriate sleep environment
    • Address sleep apnea if present (weight loss may improve)

    Stress Management:

    • Chronic stress impairs weight loss
    • Meditation, mindfulness, or therapy as appropriate
    • Social support for eating behavior changes
    • Address underlying emotional eating

    Hormonal Monitoring:

    Thyroid:

    • TSH, free T4 every 6 months
    • Weight loss may alter thyroid needs
    • Adjust replacement as needed

    HPG Axis:

    • Men: testosterone every 6 months during rapid weight loss
    • Women: menstrual tracking; if amenorrhea develops, consult reproductive endocrinology
    • Significant weight loss can suppress HPG axis via leptin reduction

    Metabolic Markers:

    • HbA1c every 3-6 months
    • Lipid panel every 3-6 months
    • Liver enzymes quarterly initially
    • Kidney function annually

    Body Composition:

    • DEXA every 6 months (gold standard)
    • Track lean mass, fat mass, visceral adipose tissue
    • Target: preserve or minimize lean mass loss during weight loss
    • Redistribute if lean mass dropping excessively (increase protein, resistance training)

    Common Intermediate Phase Issues:

    Plateau (months 6-9):

    • Expected for most patients around 40-50% of total expected weight loss
    • Reassess caloric intake (may need adjustment)
    • Reassess activity levels
    • Check adherence to injections
    • Consider adding resistance training if not already

    Decreased Appetite Extremes:

    • If inadequate caloric intake threatens lean mass: prioritize protein
    • Structured meal timing despite low hunger
    • Consider temporary dose reduction if severe

    Lean Mass Loss:

    • Monitor via DEXA
    • Intervene: increase protein, intensify resistance training
    • Consider GH peptides (Sermorelin, CJC-1295/Ipamorelin) if significant
    • Slow rate of weight loss if needed

    Expected Trajectory:

    • Month 6: 10-15% weight loss typical
    • Month 9: 15-20% weight loss typical
    • Month 12: 18-22% weight loss typical (matches REDEFINE 1 landmark cohort)
    • Month 18: plateau approaches typical nadir

    Side Effect Management:

    Persistent GI Issues:

    • Usually improve with time
    • Split injection or timing changes don't affect weekly drugs
    • Ondansetron for persistent nausea (physician guidance)
    • Eat smaller, more frequent meals

    Fatigue:

    • Ensure adequate calories (not excessive deficit)
    • Adequate sleep
    • Iron studies if persistent
    • Thyroid status check

    Hair Loss:

    • Common during rapid weight loss
    • Usually resolves when weight stabilizes
    • Adequate protein, zinc, biotin
    • Genetics a factor

    Quality of Life Monitoring:

    • Energy levels
    • Mood and mental health
    • Social eating situations
    • Body image (positive and negative)
    • Sleep quality
    • Sexual function

    Partner/Family Support:

    • Education on weight-loss drugs
    • Eating pattern changes
    • Support for new lifestyle
    • Joint meal planning

    When to Consider Transition:

    Progress to Advanced Protocol:

    • After 12-18 months of successful weight loss
    • Stable lifestyle habits established
    • Addressing long-term maintenance

    Modify Approach:

    • If progress stalls >3 months
    • If side effects become intolerable
    • If complex medical issues develop

    Reduce Dose:

    • After reaching target weight
    • If lean mass loss excessive
    • Part of maintenance planning

    Discontinue:

    • Target weight achieved with stable lifestyle
    • Medical necessity
    • Insurance coverage issues
    • Personal choice
    • Always with maintenance plan to prevent regain
    Advanced

    For experienced users approaching or maintaining target weight, typically 12-24+ months into therapy.

    Advanced Use Case 1: Maintenance After Weight Loss Goal Achievement

    Scenario: Target weight reached, transitioning to long-term maintenance.

    Protocol Options:

    Option A: Continued Full Dose Maintenance

    • Continue CagriSema 2.4 mg + 2.4 mg weekly
    • Rationale: strongest evidence for preventing regain
    • Drawback: ongoing cost and side effects

    Option B: Reduced Maintenance Dose

    • CagriSema 1.2 mg + 1.2 mg weekly (half dose)
    • Some clinical evidence for maintenance at lower doses
    • Balance: cost, convenience, prevention of regain

    Option C: Semaglutide Alone Maintenance

    • Discontinue cagrilintide, continue semaglutide 2.4 mg weekly
    • Rationale: leverage established GLP-1 monotherapy maintenance data
    • Concern: may see some regain vs dual therapy

    Option D: Gradual Discontinuation

    • Taper both drugs over 6-12 months
    • Intensive lifestyle reinforcement
    • Expect some regain (average ~50% of lost weight over 1-2 years post-discontinuation based on other weight-loss drug data)

    Advanced Use Case 2: Weight Regain After Discontinuation

    Scenario: Patient discontinued CagriSema, now regaining.

    Protocol:

    • Reassess readiness and realistic goals
    • Re-initiate CagriSema with titration (may be faster titration given prior exposure)
    • Lifestyle intervention intensification
    • Consider behavioral therapy
    • Address underlying factors (stress, sleep, medications)

    Advanced Use Case 3: Aggressive Weight Loss + Body Recomposition

    Scenario: Beyond standard weight loss — targeting specific body composition.

    Protocol:

    • CagriSema 2.4 mg + 2.4 mg weekly
    • Intensive resistance training (4-5x weekly)
    • Protein 2.0+ g/kg ideal body weight
    • Monitoring: DEXA every 3 months
    • Optional: GH peptides (Tesamorelin for visceral fat, CJC-1295/Ipamorelin for lean mass support)
    • HPG axis monitoring and support if needed
    • Medical oversight recommended

    Advanced Use Case 4: Diabetic Patient Optimization

    Scenario: Type 2 diabetes with obesity, seeking glycemic and weight control.

    Protocol:

    • CagriSema 2.4 mg + 2.4 mg weekly
    • Monitor HbA1c monthly during initiation
    • Reduce insulin/sulfonylurea doses proactively (hypoglycemia risk)
    • Coordinate with endocrinology
    • May be able to discontinue some diabetes medications
    • Target: HbA1c <7.0% and meaningful weight loss

    Advanced Use Case 5: Post-Bariatric Surgery Patient

    Scenario: Post-bariatric regain or inadequate response.

    Protocol:

    • CagriSema 2.4 mg + 2.4 mg weekly
    • Careful monitoring for GI effects (altered anatomy)
    • Adjust based on tolerance
    • Multivitamin/mineral supplementation (bariatric-appropriate)
    • Medical oversight essential
    • May need lower doses than non-bariatric patients

    Complex Monitoring for Advanced Protocols:

    • Quarterly comprehensive labs
    • DEXA every 3-6 months
    • Thyroid panel every 6 months
    • HPG axis every 6 months
    • Cardiovascular assessment annually
    • Mental health screening ongoing
    • Quality of life measures

    Integration with Multi-Peptide Protocols:

    With GH Axis:

    With Reproductive Axis:

    • Gonadorelin or HCG for men with rapid testosterone decline
    • Enclomiphene for long-term HPG maintenance
    • Reproductive endocrinology for women with amenorrhea

    With Repair/Recovery:

    • BPC-157, TB-500 for joint/tissue during increased activity
    • Thymosin-beta-4 family peptides
    • Timing: independent of CagriSema

    Long-Term Safety Surveillance:

    • Annual thyroid ultrasound if concerning history
    • Lifetime monitoring for pancreatitis signs
    • Gallbladder assessment if symptoms
    • Mental health vigilance
    • Cancer screening age-appropriate

    When to Consult Specialist:

    • Endocrinology: complex diabetes, thyroid abnormalities
    • Bariatric medicine: post-surgery or resistant cases
    • Cardiology: cardiovascular disease
    • Psychiatry: mental health concerns
    • Reproductive endocrinology: fertility issues
    • Oncology: concerning signs or findings

    Quality of Life Optimization:

    • Social eating strategies
    • Travel planning (refrigeration, time zones)
    • Stress management long-term
    • Partner/family involvement
    • Professional support (therapist, dietitian, trainer)

    Commonly Stacked With

    Cagrilintide is uniquely positioned as part of a designed combination (CagriSema) rather than a monotherapy, making stacking considerations substantially different from other peptides.

    Primary Stack: CagriSema (Cagrilintide + Semaglutide) This is the intended combination therapy:

    • Semaglutide 2.4 mg SC weekly
    • Cagrilintide 2.4 mg SC weekly (same injection day, can be same or different site)
    • Combined weight loss: 20-22% at 68 weeks
    • Mechanism: dual-axis anorexia (GLP-1 + amylin) without proportional GI increase

    Cagrilintide Monotherapy:

    • Possible at 4.5 mg weekly (Phase 2-established dose)
    • Weight loss: 10-11% at 26 weeks
    • Less common than CagriSema positioning; most commercial path emphasizes combination
    • Potentially useful in patients unable to tolerate GLP-1 agonists

    With Tirzepatide (Theoretical):

    • Hypothetical GLP-1/GIP + amylin combination
    • No clinical evidence; not commercially developed
    • Risk: unpredictable combined GI burden
    • Not recommended without clinical trial data

    With Retatrutide (Theoretical):

    • GLP-1/GIP/glucagon + amylin would be quadruple mechanism
    • Pre-clinical rationale possible
    • No human data
    • Likely too aggressive for initial development

    Lifestyle + CagriSema: The most evidence-based stack — CagriSema combined with:

    • Structured resistance training (preserves lean mass during weight loss)
    • Adequate protein intake (1.6-2.0 g/kg ideal body weight)
    • Caloric deficit nutritionally balanced
    • Monitoring body composition (DEXA) rather than just scale weight
    • Psychological support for eating behavior changes

    With Other Peptides:

    Growth Hormone Peptides for Lean Mass Preservation:

    • Sermorelin, CJC-1295 + Ipamorelin, Tesamorelin
    • Rationale: preserve lean mass during aggressive weight loss
    • Evidence: limited direct combination data
    • Consideration: timing (GH peptides in evening; cagrilintide any time weekly)

    Thyroid Support:

    • Not routinely indicated
    • Some rapid weight loss causes mild T3/T4 changes
    • Monitor TSH/free T4 every 3-6 months during aggressive weight loss
    • Adjust existing thyroid replacement if needed

    HPG Axis Preservation:

    • Rapid weight loss can suppress testosterone in men and menstrual cyclicity in women
    • Gonadorelin or Enclomiphene for men losing testosterone
    • Reproductive endocrinology consultation for women with amenorrhea

    Repair Peptides:

    • BPC-157, TB-500
    • No direct interaction with cagrilintide mechanism
    • May support joint/tissue health during weight loss and increased activity
    • Timing independent

    Immune Support:

    Avoid These Combinations:

    • Cagrilintide + pramlintide: same receptor target; redundant and potentially excessive
    • High-dose sulfonylureas or insulin without dose reduction: hypoglycemia risk (especially in diabetic patients)
    • Other weight-loss drugs without physician oversight: bupropion, phentermine, topiramate may produce unpredictable combined effects
    • Undisclosed research-grade supplementation without physician awareness

    Sequencing Strategies:

    • Ramp-up: start cagrilintide 0.3 mg weekly, titrate over 12-16 weeks to 2.4 mg
    • If on semaglutide: add cagrilintide 0.3 mg weekly, titrate as tolerated
    • If tirzepatide naive: CagriSema is the evidence-based combination; adding amylin to tirzepatide has no clinical data
    • Plateau management: if weight loss plateaus on semaglutide alone, adding cagrilintide (CagriSema) is evidence-based

    Monitoring Stack:

    • Weight: weekly during titration, monthly maintenance
    • Body composition: DEXA or impedance baseline and every 3-6 months
    • Lipid panel, HbA1c, liver enzymes baseline and every 3-6 months
    • Thyroid function baseline and annually
    • HPG axis (testosterone, menstrual cyclicity) as relevant

    Discontinuation Planning: Weight regain after discontinuation is well-documented for all weight-loss drugs. Strategies to minimize regain:

    • Gradual dose reduction rather than abrupt stop
    • Aggressive lifestyle reinforcement in final months
    • Maintenance lower-dose consideration (emerging practice)
    • Body composition monitoring to detect lean mass loss
    • Psychological support for behavioral maintenance

    Side Effects & Safety

    Cagrilintide's side-effect profile is dominated by gastrointestinal effects similar to but distinct from GLP-1 agonists, with some amylin-specific considerations. **Most Common Side Effects (from trials):** **Gastrointestinal (dose-dependent):** - **Nausea**: in the Phase 2 monotherapy trial, roughly 20%-47% across cagrilintide doses vs 18% placebo (overall GI adverse events 41%-63% vs 32% placebo) - generally mild-to-moderate, tends to decrease with continued dosing - **Vomiting**: more common at higher doses; less common than with GLP-1 agonists at equivalent weight loss - **Diarrhea**: moderate frequency - **Constipation**: less common than with semaglutide - **Decreased appetite**: expected and desired effect; can become problematic if excessive - **Dyspepsia / abdominal discomfort**: moderate frequency - **Early satiety**: expected effect, sometimes extreme **Metabolic Effects:** - **Fatigue**: modest, especially during rapid weight loss - **Headache**: mild-to-moderate, transient - **Dizziness**: especially in dehydrated individuals or with rapid dose escalation - **Injection site reactions**: mild, transient **CagriSema-Specific Considerations:** When combined with semaglutide, GI tolerability is broadly similar to semaglutide alone in the Phase 1b trial, suggesting the amylin component does not proportionally worsen GI adverse events despite adding a mechanism of action. In the larger Phase 3 REDEFINE trials, GI adverse events were common (about 72-80% with CagriSema vs 34-40% placebo) but mostly transient and mild-to-moderate. **Rare Serious Adverse Events:** - **Pancreatitis**: theoretical concern with incretin-amylin axis modulation; not clearly elevated in trials but monitoring required - **Gallbladder disease**: elevated risk during rapid weight loss (common with any weight-loss drug) - **Hypoglycemia**: rare with monotherapy in non-diabetic patients; more common when combined with insulin or sulfonylureas in diabetic patients **Amylin-Specific Considerations:** **Amyloidogenicity Concerns:** Native amylin is amyloidogenic and forms pancreatic amyloid in type 2 diabetes. Clinical amylin analogs (including cagrilintide) incorporate proline substitutions to prevent amyloid formation. Clinical trials to date have shown no evidence of iatrogenic amyloidosis from cagrilintide, but this remains a theoretical long-term consideration. **Calcitonin Receptor Effects:** Cagrilintide retains some calcitonin receptor binding, raising theoretical concerns about: - Thyroid C-cell effects (as with GLP-1 agonists) - Calcium/phosphate homeostasis (calcitonin's native role) Trials to date have not shown clinically meaningful effects in these domains. **Thyroid C-Cell Tumors:** Like GLP-1 agonists, cagrilintide carries a theoretical concern about medullary thyroid cancer risk based on rodent studies. CagriSema labeling will likely inherit the MTC/MEN2 contraindication from semaglutide. **Specific Populations:** **Pregnancy**: Like all weight-loss drugs, cagrilintide is not indicated during pregnancy. Weight loss is contraindicated during pregnancy. Women of reproductive potential should use effective contraception during treatment and discontinue before planned conception. **Elderly**: Limited data in patients >75 years; may require more careful dose titration given altered pharmacokinetics and increased fall risk with weight loss. **Renal Impairment**: Not primarily renally cleared, but caution warranted in severe renal impairment until more data accumulates. **Hepatic Impairment**: Limited data; exercise caution in severe hepatic dysfunction. **Children/Adolescents**: Not yet studied; pediatric obesity trials may follow adult approval. **Red Flags Requiring Discontinuation:** - Severe persistent nausea/vomiting unresponsive to supportive care - Signs of pancreatitis (severe abdominal pain radiating to back) - Signs of gallbladder disease (RUQ pain, jaundice) - Signs of hypoglycemia requiring rescue (especially in diabetic patients) - Psychiatric symptoms: significant mood changes - Severe injection site reactions - Any sign of thyroid abnormality (neck mass, dysphagia, dyspnea, hoarseness) **Long-Term Safety:** As a relatively new molecule (albeit with an amylin receptor mechanism dating to pramlintide's 2005 approval), cagrilintide lacks very long-term (5-10+ year) safety data. Post-marketing surveillance will be essential for: - Cancer signals (particularly thyroid) - Cardiovascular outcomes - Psychiatric effects - Weight regain trajectory after discontinuation - Effects on lean muscle mass **Comparison with Other Weight-Loss Drugs:** Cagrilintide (and by extension CagriSema) appears to have: - Similar overall GI tolerability to semaglutide (not proportionally worse despite dual mechanism) - Better than liraglutide for convenience (once weekly vs daily) - Less long-term data than liraglutide, semaglutide, or tirzepatide

    Contraindications

    **Absolute Contraindications:** - **Personal or family history of medullary thyroid carcinoma (MTC)** - **Multiple endocrine neoplasia type 2 (MEN2)** - **Known hypersensitivity** to cagrilintide, semaglutide, or any component - **Pregnancy** (weight loss contraindicated) - **Active eating disorder** (anorexia nervosa, severe bulimia) - **Severe untreated psychiatric conditions** **Relative Contraindications (Require Careful Evaluation):** - **History of pancreatitis**: not absolute but high caution - **Severe gastroparesis**: may worsen - **Gallbladder disease**: increased risk during rapid weight loss - **Inflammatory bowel disease**: caution with GI effects - **Severe renal impairment** (eGFR <30): limited data - **Severe hepatic impairment**: limited data - **Age >75**: careful titration needed - **Children/adolescents**: not yet studied **Drug Interactions:** **Medications Requiring Adjustment:** - **Insulin**: may need 20-40% dose reduction (hypoglycemia risk) - **Sulfonylureas**: consider dose reduction or discontinuation - **Thyroid replacement**: monitor and adjust as weight changes - **Levothyroxine**: absorption may be affected; separate by 30 min+ - **Oral contraceptives**: absorption may be altered; barrier backup recommended - **Warfarin**: monitor INR (altered absorption possible) **Medications to Use with Caution:** - **Other GLP-1 agonists**: avoid concurrent use (redundant, increased AE) - **Other amylin analogs** (pramlintide): avoid concurrent use - **Opioids**: may worsen constipation - **Sedatives**: may worsen dizziness - **Lithium**: altered clearance possible **Medications Compatible:** - Most antihypertensives - Statins - Metformin (often beneficial combination) - SSRIs (monitor mood changes) - Most thyroid medications (with monitoring) - Most HRT (estrogen, testosterone) **Medical Conditions Requiring Caution:** **Gastrointestinal:** - Gastroparesis: worsening risk - Inflammatory bowel disease: caution - Peptic ulcer disease: monitor - History of bowel obstruction: contraindicated **Pancreatic:** - History of pancreatitis: high caution - Pancreatic insufficiency: monitor - Pancreatic cancer risk: theoretical **Thyroid:** - Medullary thyroid carcinoma (personal or family): contraindicated - MEN2 syndrome: contraindicated - Benign thyroid nodules: monitor - Autoimmune thyroiditis: manage thyroid function separately **Gallbladder:** - Gallstones: increased risk with rapid weight loss - Previous cholecystectomy: no additional contraindication - Active symptoms: manage before starting **Cardiovascular:** - Recent myocardial infarction: delay start - Severe heart failure: monitor - Hypertension: typically improves with weight loss **Renal:** - Mild-moderate impairment: no major concerns - Severe impairment (eGFR <30): limited data - Hemodialysis: not well-studied **Hepatic:** - Non-alcoholic fatty liver: typically improves with weight loss - Severe cirrhosis: limited data - Alcoholic liver disease: manage separately **Psychiatric:** - Depression: monitor closely (any weight-loss drug can affect mood) - Anxiety disorders: monitor - History of suicidal ideation: careful monitoring - Eating disorders: contraindicated if active **Pregnancy/Reproductive:** - Pregnancy: absolute contraindication - Breastfeeding: not well-studied - Effective contraception during treatment - Pre-conception: discontinue 4-6 weeks before **When to Stop Immediately:** - Anaphylactoid/severe hypersensitivity reaction - Severe persistent pancreatitis symptoms - Suspected medullary thyroid cancer - Severe gallbladder disease - Severe psychiatric emergency - Pregnancy (discovery or planning) - Severe unexplained weight loss **When to Consult Physician:** - Severe or persistent GI symptoms - Suspected pancreatitis - New thyroid symptoms (neck mass, dysphagia) - Gallbladder symptoms - Significant mood changes - Severe fatigue - Unexpected labs - Pregnancy plans - New medical conditions **Pre-Treatment Assessment:** - Complete medical history - Medication reconciliation - Baseline labs (complete metabolic panel, lipids, HbA1c, TSH, liver enzymes) - Mental health screening - Physical exam - ECG if cardiovascular concerns - Pregnancy test if applicable - Patient education on risks/benefits **Monitoring Schedule:** - **Baseline**: complete evaluation - **Month 1**: clinical visit, symptoms review - **Month 3**: labs + clinical assessment - **Month 6**: labs + body composition + complete reassessment - **Month 12**: annual evaluation - **Ongoing**: symptom tracking, quality of life **Integration with Medical Care:** CagriSema/cagrilintide use benefits from clinical oversight: - Primary care with weight management expertise - Endocrinology for complex diabetes or thyroid - Bariatric medicine for advanced cases - Nutrition counseling - Mental health support Solo use is possible but coordination with physicians optimizes outcomes and safety. Insurance coverage often requires specific documentation and monitoring.

    Check interactions with the Interaction Checker →

    Additional Notes

    Standard Dose Ranges:

    Cagrilintide Monotherapy (Phase 2 established):

    • Initiation: 0.3 mg SC weekly
    • Titration: 0.6 1.2 2.4 4.5 mg weekly
    • Maintenance: 2.4-4.5 mg weekly
    • Increment interval: every 4 weeks

    CagriSema Combination (Phase 3 standard):

    • Semaglutide 2.4 mg + Cagrilintide 2.4 mg SC weekly
    • ~16-week co-escalation to full dose
    • Maintenance: ongoing weekly dosing

    Dose Escalation Rationale: The titration protocol is designed to minimize GI side effects. Most nausea and vomiting occurs during dose escalation phases. Slower titration may be warranted in:

    • Patients with severe initial GI response
    • Elderly patients
    • Patients with complex medical conditions

    Dose Reduction Strategies:

    • If intolerable nausea: reduce to previous tolerated dose for 4 more weeks, then re-escalate
    • If severe GI issues persist: consider switching to monotherapy (semaglutide or cagrilintide alone)
    • If weight loss excessive: reduce maintenance dose
    • If lean mass loss concerning: optimize protein/exercise first, then consider dose reduction

    Dose Dependence Relationships:

    Weight Loss vs Dose (cagrilintide monotherapy - Phase 2, Lau et al. 2021, 26 weeks):

    • Across the full 0.3-4.5 mg dose range, mean weight loss was 6.0%-10.8% vs 3.0% for placebo (the dose-response curve is relatively flat above ~1 mg)
    • 4.5 mg (highest dose): 10.8%, exceeding once-daily liraglutide 3.0 mg (9.0%)
    • Reference: Lau et al., 2021

    Side Effects vs Dose:

    • Higher doses: more nausea, vomiting
    • Typically manageable with titration
    • Most GI effects diminish with continued dosing

    Timing Considerations:

    Day of Week:

    • Any day works
    • Consistency matters more than specific day
    • Sunday or Monday common (align with weekly rhythm)
    • Avoid Friday/Saturday (GI effects during social eating)

    Time of Day:

    • Any time works (long half-life smooths effects)
    • Morning may be preferable for those with evening social eating
    • Consistency matters more than specific time

    Injection Site Rotation:

    • Abdomen (2+ inches from navel)
    • Thigh (outer)
    • Upper arm (back)
    • Rotate sites each injection
    • Record to avoid lipohypertrophy

    Source Quality:

    Pharmaceutical-Grade (Preferred):

    • Once FDA-approved, use commercial product
    • Clinical trial supply during trials
    • Compounded from licensed pharmacy (current off-label option)
    • USP-grade peptide verification

    Research-Grade (Lower Quality):

    • Grey-market sources
    • Variable purity
    • Storage concerns
    • Not recommended for therapeutic use

    Recognizing Quality:

    • Clear labeling
    • Expected concentration
    • Reputable source
    • Third-party COA
    • Proper storage during shipping

    Special Considerations:

    Concurrent Medications:

    • Insulin: may need 20-40% reduction
    • Sulfonylureas: consider discontinuation
    • Thyroid replacement: may need adjustment
    • Oral contraceptives: delayed absorption during rapid gastric emptying change
    • All prescriptions: inform physicians

    Pregnancy/Breastfeeding:

    • Not indicated during pregnancy
    • Discontinue before planned conception
    • Not studied during lactation
    • Effective contraception during treatment

    Elderly (>75):

    • Slower titration
    • Lower doses may be sufficient
    • Monitor for falls with weight loss
    • Assess cognitive status

    Pediatric:

    • Not yet studied
    • Pediatric trials may follow adult approval
    • Childhood obesity is increasing
    • Specific pediatric considerations will apply

    Renal Impairment:

    • Not primarily renally cleared
    • Monitor in severe renal disease
    • Adjust based on response and tolerance

    Hepatic Impairment:

    • Limited data
    • Caution in severe hepatic dysfunction
    • Monitor liver enzymes

    Surgical Considerations:

    • GLP-1 agonist component associated with retained gastric contents
    • Discontinue before surgery per anesthesia guidance
    • Coordinate with surgical team
    • Resume after recovery

    Cost Considerations:

    • Expected to be expensive (similar to other GLP-1 combination therapies)
    • Insurance coverage variable
    • Manufacturer programs may be available
    • Cost-benefit analysis for individual patients
    • Long-term investment in health

    Storage:

    • Refrigerate (2-8 deg C)
    • Do not freeze
    • Light protection preferred
    • Follow specific product instructions at approval

    Where to Buy Cagrilintide

    Compare 4 listings across 4 vendors, from $49.99

    Frequently Asked Questions

    What is the recommended Cagrilintide dosage?

    Dosage for Cagrilintide varies by protocol. Consult a qualified healthcare provider.

    How often should I take Cagrilintide?

    Once weekly

    Does Cagrilintide need to be cycled?

    Cycling requirements depend on the protocol. Follow established research guidelines.

    What are Cagrilintide side effects?

    Cagrilintide's side-effect profile is dominated by gastrointestinal effects similar to but distinct from GLP-1 agonists, with some amylin-specific considerations. **Most Common Side Effects (from trials):** **Gastrointestinal (dose-dependent):** - **Nausea**: in the Phase 2 monotherapy trial, roughly 20%-47% across cagrilintide doses vs 18% placebo (overall GI adverse events 41%-63% vs 32% placebo) - generally mild-to-moderate, tends to decrease with continued dosing - **Vomiting**: more common at higher doses; less common than with GLP-1 agonists at equivalent weight loss - **Diarrhea**: moderate frequency - **Constipation**: less common than with semaglutide - **Decreased appetite**: expected and desired effect; can become problematic if excessive - **Dyspepsia / abdominal discomfort**: moderate frequency - **Early satiety**: expected effect, sometimes extreme **Metabolic Effects:** - **Fatigue**: modest, especially during rapid weight loss - **Headache**: mild-to-moderate, transient - **Dizziness**: especially in dehydrated individuals or with rapid dose escalation - **Injection site reactions**: mild, transient **CagriSema-Specific Considerations:** When combined with semaglutide, GI tolerability is broadly similar to semaglutide alone in the Phase 1b trial, suggesting the amylin component does not proportionally worsen GI adverse events despite adding a mechanism of action. In the larger Phase 3 REDEFINE trials, GI adverse events were common (about 72-80% with CagriSema vs 34-40% placebo) but mostly transient and mild-to-moderate. **Rare Serious Adverse Events:** - **Pancreatitis**: theoretical concern with incretin-amylin axis modulation; not clearly elevated in trials but monitoring required - **Gallbladder disease**: elevated risk during rapid weight loss (common with any weight-loss drug) - **Hypoglycemia**: rare with monotherapy in non-diabetic patients; more common when combined with insulin or sulfonylureas in diabetic patients **Amylin-Specific Considerations:** **Amyloidogenicity Concerns:** Native amylin is amyloidogenic and forms pancreatic amyloid in type 2 diabetes. Clinical amylin analogs (including cagrilintide) incorporate proline substitutions to prevent amyloid formation. Clinical trials to date have shown no evidence of iatrogenic amyloidosis from cagrilintide, but this remains a theoretical long-term consideration. **Calcitonin Receptor Effects:** Cagrilintide retains some calcitonin receptor binding, raising theoretical concerns about: - Thyroid C-cell effects (as with GLP-1 agonists) - Calcium/phosphate homeostasis (calcitonin's native role) Trials to date have not shown clinically meaningful effects in these domains. **Thyroid C-Cell Tumors:** Like GLP-1 agonists, cagrilintide carries a theoretical concern about medullary thyroid cancer risk based on rodent studies. CagriSema labeling will likely inherit the MTC/MEN2 contraindication from semaglutide. **Specific Populations:** **Pregnancy**: Like all weight-loss drugs, cagrilintide is not indicated during pregnancy. Weight loss is contraindicated during pregnancy. Women of reproductive potential should use effective contraception during treatment and discontinue before planned conception. **Elderly**: Limited data in patients >75 years; may require more careful dose titration given altered pharmacokinetics and increased fall risk with weight loss. **Renal Impairment**: Not primarily renally cleared, but caution warranted in severe renal impairment until more data accumulates. **Hepatic Impairment**: Limited data; exercise caution in severe hepatic dysfunction. **Children/Adolescents**: Not yet studied; pediatric obesity trials may follow adult approval. **Red Flags Requiring Discontinuation:** - Severe persistent nausea/vomiting unresponsive to supportive care - Signs of pancreatitis (severe abdominal pain radiating to back) - Signs of gallbladder disease (RUQ pain, jaundice) - Signs of hypoglycemia requiring rescue (especially in diabetic patients) - Psychiatric symptoms: significant mood changes - Severe injection site reactions - Any sign of thyroid abnormality (neck mass, dysphagia, dyspnea, hoarseness) **Long-Term Safety:** As a relatively new molecule (albeit with an amylin receptor mechanism dating to pramlintide's 2005 approval), cagrilintide lacks very long-term (5-10+ year) safety data. Post-marketing surveillance will be essential for: - Cancer signals (particularly thyroid) - Cardiovascular outcomes - Psychiatric effects - Weight regain trajectory after discontinuation - Effects on lean muscle mass **Comparison with Other Weight-Loss Drugs:** Cagrilintide (and by extension CagriSema) appears to have: - Similar overall GI tolerability to semaglutide (not proportionally worse despite dual mechanism) - Better than liraglutide for convenience (once weekly vs daily) - Less long-term data than liraglutide, semaglutide, or tirzepatide

    Where can I buy Cagrilintide?

    Compare 4 listings from 4 vendors on our price comparison page, starting from $49.99.

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free